These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 34678987)
1. Low-Dose Neubotulinum Toxin A versus Low-Dose Abobotulinum Toxin A Injection for the Treatment of Cervical Dystonia: A Multicenter, 48-Week, Prospective, Double-Blinded, Randomized Crossover Design Study. Kongsaengdao S; Arayawithchanont A; Samintharapanya K; Rojanapitayakorn P; Maneeton B; Maneeton N Toxins (Basel); 2021 Oct; 13(10):. PubMed ID: 34678987 [TBL] [Abstract][Full Text] [Related]
2. Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study. Kongsaengdao S; Maneeton N; Maneeton B Neuropsychiatr Dis Treat; 2018; 14():1119-1124. PubMed ID: 29731634 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial. Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248 [TBL] [Abstract][Full Text] [Related]
5. Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study. Mordin M; Masaquel C; Abbott C; Copley-Merriman C BMJ Open; 2014 Oct; 4(10):e005150. PubMed ID: 25324317 [TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type B for cervical dystonia. Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Brin MF; Lew MF; Adler CH; Comella CL; Factor SA; Jankovic J; O'Brien C; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M Neurology; 1999 Oct; 53(7):1431-8. PubMed ID: 10534247 [TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Pappert EJ; Germanson T; Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274 [TBL] [Abstract][Full Text] [Related]
9. An analysis of the efficacy of botulinum neurotoxin type a in treating cervical dystonia. Zhou X; Li ZF; Guo XZ; Wei Q; Niu YN; Li M; Xia JN; Chen LP Technol Health Care; 2024; 32(4):2421-2430. PubMed ID: 38073352 [TBL] [Abstract][Full Text] [Related]
10. Botulinum Toxin Type A Injection for Cervical Dystonia in Adults with Dyskinetic Cerebral Palsy. Yi YG; Kim K; Yi Y; Choi YA; Leigh JH; Bang MS Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29772695 [TBL] [Abstract][Full Text] [Related]
11. Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study. Patel AT; Lew MF; Dashtipour K; Isaacson S; Hauser RA; Ondo W; Maisonobe P; Wietek S; Rubin B; Brashear A PLoS One; 2021; 16(2):e0245827. PubMed ID: 33524060 [TBL] [Abstract][Full Text] [Related]
12. A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia. Hu W; Rundle-Gonzalez V; Kulkarni SJ; Martinez-Ramirez D; Almeida L; Okun MS; Wagle Shukla A Parkinsonism Relat Disord; 2019 Jun; 63():195-198. PubMed ID: 30837195 [TBL] [Abstract][Full Text] [Related]
13. KinesioTaping after botulinum toxin type A for cervical dystonia in adult patients. Dec-Ćwiek M; Porębska K; Sawczyńska K; Kubala M; Witkowska M; Zmijewska K; Antczak J; Pera J Brain Behav; 2022 Apr; 12(4):e2541. PubMed ID: 35238494 [TBL] [Abstract][Full Text] [Related]
14. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). Jankovic J; Adler CH; Charles D; Comella C; Stacy M; Schwartz M; Manack Adams A; Brin MF J Neurol Sci; 2015 Feb; 349(1-2):84-93. PubMed ID: 25595221 [TBL] [Abstract][Full Text] [Related]
15. Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance. Samotus O; Lee J; Jog M J Neurol; 2018 Jun; 265(6):1269-1278. PubMed ID: 29557988 [TBL] [Abstract][Full Text] [Related]
16. Conversion to AbobotulinumtoxinA Increases Waning Time and Efficacy for Cervical Dystonia. Samotus O; Jog M Mov Disord Clin Pract; 2023 May; 10(5):756-763. PubMed ID: 37205243 [TBL] [Abstract][Full Text] [Related]
17. The clinical utility of botulinum toxin injections targeted at the motor endplate zone in cervical dystonia. Delnooz CC; Veugen LC; Pasman JW; Lapatki BG; van Dijk JP; van de Warrenburg BP Eur J Neurol; 2014 Dec; 21(12):1486-e98. PubMed ID: 25060697 [TBL] [Abstract][Full Text] [Related]
18. Pallidal neurostimulation versus botulinum toxin injections in the treatment of cervical dystonia: protocol of a randomized, sham-controlled trial (StimTox-CD). Odorfer TM; Malzahn U; Matthies C; Heuschmann PU; Volkmann J Neurol Res Pract; 2019; 1():2. PubMed ID: 33324868 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of single-photon emission computed tomography aided botulinum toxin injection in cervical dystonia: A double-blind, randomized study. Teng F; Malam Djibo I; Chen S; Su J; Pan Y; Zhang X; Xu Y; Feng L; Pan L; Jin L Parkinsonism Relat Disord; 2021 Oct; 91():77-82. PubMed ID: 34537494 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Chinnapongse RB; Lew MF; Ferreira JJ; Gullo KL; Nemeth PR; Zhang Y Clin Neuropharmacol; 2012; 35(5):215-23. PubMed ID: 22932474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]